PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study To Assess The Safety, Tolerability And Pharmacokinetics Of PF-06282999 Administered Orally In Healthy Adult Subjects
- First Posted Date
- 2012-06-25
- Last Posted Date
- 2013-03-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 42
- Registration Number
- NCT01626976
- Locations
- 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium
Prospective Evaluation of the Radiographic Efficacy of Enbrel
- First Posted Date
- 2012-06-20
- Last Posted Date
- 2019-08-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1821
- Registration Number
- NCT01623752
A Phase 1 Study To Evaluate The Safety And Tolerability Of PF-06252616 In Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Biological: PF-06252616Biological: PF-06252161Drug: Placebo
- First Posted Date
- 2012-06-11
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 86
- Registration Number
- NCT01616277
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
A Study to Assess Safety, Tolerability and Pharmacokinetics of Ceftaroline in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-06-05
- Last Posted Date
- 2017-09-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 41
- Registration Number
- NCT01612507
- Locations
- 🇬🇧
Research site, London, United Kingdom
Burden of Disease Study In Patients With Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP) orTransthyretin Cardiomyopathy (TTR-CM) And Caregivers
Completed
- Conditions
- Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP)Transthyretin Cardiomyopathy (TTR-CM)Senile Systemic Amyloidosis (SSA)Familial Amyloid Cardiomyopathy
- Interventions
- Other: No drug
- First Posted Date
- 2012-05-23
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT01604122
Pilot Study Of Pregabalin And Prediction Of Treatment Response In Patients With Postherpetic Neuralgia
- First Posted Date
- 2012-05-22
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 9
- Registration Number
- NCT01603394
- Locations
- 🇿🇦
Pfizer Investigational Site, Paarl, Western Cape, South Africa
A Pharmacokinetic Study Comparing PF-05280014 And Trastuzumab In Healthy Male Volunteers (REFLECTIONS B327-01)
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Biological: HerceptinBiological: PF-05280014
- First Posted Date
- 2012-05-22
- Last Posted Date
- 2012-12-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 105
- Registration Number
- NCT01603264
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
Study to Estimate the Pharmacokinetics, Bioavailability and Effect of Food on Single Dose Modified-release Lersivirine 500 mg in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2012-05-22
- Last Posted Date
- 2012-09-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT01603485
- Locations
- 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium
Efficacy and Safety of AN2728 Topical Ointment to Treat Adolescents With Atopic Dermatitis
Phase 2
Completed
- Conditions
- Dermatitis, Atopic
- Interventions
- Drug: AN2728 Topical Ointment, 2% QDDrug: AN2728 Topical Ointment, 2% BIDDrug: AN2728 Topical Ointment, 0.5% BIDDrug: AN2728 Topical Ointment, 0.5% QD
- First Posted Date
- 2012-05-21
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 86
- Registration Number
- NCT01602341
- Locations
- 🇦🇺
Anacor Investigational Site, Fremantle, Western Australia, Australia
Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia
Phase 3
Withdrawn
- Conditions
- Community Acquired Bacterial PneumoniaComplicated Intra-Abdominal Infection
- Interventions
- First Posted Date
- 2012-05-21
- Last Posted Date
- 2013-02-22
- Lead Sponsor
- Pfizer
- Registration Number
- NCT01602874